Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of LY2484595 alone and with statins in adults with hypercholesterolemia or low HDL-C
NL-OMON36417Phase 2Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of evacetrapib in hypercholesterolemia and Hypo-HDL cholesterolemia (HALP) (10 arms), sponsored by Eli Lilly and Company. Primary endpoints: Change in HDL-C, Change in direct LDL-C and 8 more. Planned start Apr 2010; status: not yet recruiting.
02
Drugs
evacetrapib
03
Conditions
hypercholesterolemiaHypo-HDL cholesterolemia (HALP)
Beyond the preview
Go deeper on NL-OMON36417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36417.